Issue

Vol. 10 No. 4 (2018)

In Vivo Tumor-Targeted Dual-Modality PET/Optical Imaging with a Yolk/Shell-Structured Silica Nanosystem

https://doi.org/10.1007/s40820-018-0216-2
Sixiang Shi
Department of Materials Science and Engineering, University of Wisconsin-Madison, Madison, WI, USA
Feng Chen
Department of Radiology, University of Wisconsin-Madison, Madison, WI 53705-2275, USA
Shreya Goel
Department of Materials Science and Engineering, University of Wisconsin-Madison, Madison, WI, USA
Stephen A. Graves
Department of Medical Physics, University of Wisconsin- Madison, Madison, WI, USA
Haiming Luo
Department of Radiology, University of Wisconsin-Madison, Madison, WI 53705-2275, USA
Charles P. Theuer
TRACON Pharmaceuticals, Inc., San Diego, CA, USA
Jonathan W. Engle
Department of Medical Physics, University of Wisconsin- Madison, Madison, WI, USA
Weibo Cai
Department of Materials Science and Engineering, University of Wisconsin-Madison, Madison, WI, USA

Corresponding Author: Weibo Cai

wcai@uwhealth.org

Nano-Micro Letters, Vol. 10 No. 4 (2018), Article Number: 65

Abstract

Silica nanoparticles have been one of the most promising nanosystems for biomedical applications due to their facile surface chemistry and non-toxic nature. However, it is still challenging to effectively deliver them into tumor sites and noninvasively visualize their in vivo biodistribution with excellent sensitivity and accuracy for effective cancer diagnosis. In this study, we design a yolk/shell-structured silica nanosystem 64Cu-NOTA-QD@HMSN-PEG-TRC105, which can be employed for tumor vasculature targeting and dual-modality PET/optical imaging, leading to superior targeting specificity, excellent imaging capability and more reliable diagnostic outcomes. By combining vasculature targeting, pH-sensitive drug delivery, and dual-modality imaging into a single platform, as-designed yolk/shell-structured silica nanosystems may be employed for the future image-guided tumor-targeted drug delivery, to further enable cancer theranostics.


Highlights:


1 A hybrid yolk/shell nanosystem was generated with quantum dot as the core and hollow mesoporous silica as the shell.
2 Dual-modality PET/optical imaging was conducted to achieve synergistic cancer diagnosis that combines the advantages of both PET and optical imaging.
3 Successful tumor vasculature targeting was achieved, which significantly enhanced tumor retention and targeting specificity.

Keywords

Hollow mesoporous silica nanoparticle (HMSN) Quantum dot (QD) Molecular imaging Positron emission tomography (PET) Optical imaging CD105/endoglin
Shi, Sixiang, Feng Chen, Shreya Goel, Stephen A. Graves, Haiming Luo, Charles P. Theuer, Jonathan W. Engle, and Weibo Cai. 2018. “In Vivo Tumor-Targeted Dual-Modality PET/Optical Imaging With a Yolk/Shell-Structured Silica Nanosystem”. Nano-Micro Letters 10 (4):65. https://doi.org/10.1007/s40820-018-0216-2.
Download Citation
Endnote/Zotero/Mendeley (RIS)
BibTeX
References
  1. H. Cabral, N. Nishiyama, K. Kataoka, Supramolecular nanodevices: from design validation to theranostic nanomedicine. Acc. Chem. Res. 44(10), 999–1008 (2011). https://doi.org/10.1021/ar200094a
  2. X. Ma, Y. Zhao, X.-J. Liang, Theranostic nanoparticles engineered for clinic and pharmaceutics. Acc. Chem. Res. 44(10), 1114–1122 (2011). https://doi.org/10.1021/ar2000056
  3. W. Cai, X. Chen, Nanoplatforms for targeted molecular imaging in living subjects. Small 3(11), 1840–1854 (2007). https://doi.org/10.1002/smll.200700351
  4. D.E. Lee, H. Koo, I.C. Sun, J.H. Ryu, K. Kim, I.C. Kwon, Multifunctional nanoparticles for multimodal imaging and theragnosis. Chem. Soc. Rev. 41(7), 2656–2672 (2012). https://doi.org/10.1039/c2cs15261d
  5. J. Rieffel, U. Chitgupi, J.F. Lovell, Recent advances in higher-order, multimodal, biomedical imaging agents. Small 11(35), 4445–4461 (2015). https://doi.org/10.1002/smll.201500735
  6. S. Shi, F. Chen, W. Cai, Biomedical applications of functionalized hollow mesoporous silica nanoparticles: focusing on molecular imaging. Nanomedicine 8(12), 2027–2039 (2013). https://doi.org/10.2217/nnm.13.177
  7. J.L. Vivero-Escoto, R.C. Huxford-Phillips, W. Lin, Silica-based nanoprobes for biomedical imaging and theranostic applications. Chem. Soc. Rev. 41(7), 2673–2685 (2012). https://doi.org/10.1039/c2cs15229k
  8. F. Tang, L. Li, D. Chen, Mesoporous silica nanoparticles: synthesis, biocompatibility and drug delivery. Adv. Mater. 24(12), 1504–1534 (2012). https://doi.org/10.1002/adma.201104763
  9. X. Fang, X. Zhao, W. Fang, C. Chen, N. Zheng, Self-templating synthesis of hollow mesoporous silica and their applications in catalysis and drug delivery. Nanoscale 5(6), 2205–2218 (2013). https://doi.org/10.1039/c3nr34006f
  10. S.H. Wu, C.Y. Mou, H.P. Lin, Synthesis of mesoporous silica nanoparticles. Chem. Soc. Rev. 42(9), 3862–3875 (2013). https://doi.org/10.1039/c3cs35405a
  11. F. Chen, H. Hong, S. Shi, S. Goel, H.F. Valdovinos, R. Hernandez, C.P. Theuer, T.E. Barnhart, W. Cai, Engineering of hollow mesoporous silica nanoparticles for remarkably enhanced tumor active targeting efficacy. Sci. Rep. 4, 5080 (2014). https://doi.org/10.1038/srep05080
  12. R. Chakravarty, S. Goel, H. Hong, F. Chen, H.F. Valdovinos, R. Hernandez, T.E. Barnhart, W. Cai, Hollow mesoporous silica nanoparticles for tumor vasculature targeting and pet image-guided drug delivery. Nanomedicine 10(8), 1233–1246 (2015). https://doi.org/10.2217/nnm.14.226
  13. S. Goel, C.A. Ferreira, F. Chen, P.A. Ellison, C.M. Siamof, T.E. Barnhart, W. Cai, Activatable hybrid nanotheranostics for tetramodal imaging and synergistic photothermal/photodynamic therapy. Adv. Mater. 30(6), 1704367 (2018). https://doi.org/10.1002/adma.201704367
  14. J. Culver, W. Akers, S. Achilefu, Multimodality molecular imaging with combined optical and spect/pet modalities. J. Nucl. Med. 49(2), 169–172 (2008). https://doi.org/10.2967/jnumed.107.043331
  15. W. Cai, X. Chen, Multimodality molecular imaging of tumor angiogenesis. J. Nucl. Med. 49, 113S–128S (2008). https://doi.org/10.2967/jnumed.107.045922
  16. S.N. Histed, M.L. Lindenberg, E. Mena, B. Turkbey, P.L. Choyke, K.A. Kurdziel, Review of functional/anatomical imaging in oncology. Nucl. Med. Commun. 33(4), 349–361 (2012). https://doi.org/10.1097/MNM.0b013e32834ec8a5
  17. T.F. Massoud, S.S. Gambhir, Molecular imaging in living subjects: seeing fundamental biological processes in a new light. Genes Dev. 17(5), 545–580 (2003). https://doi.org/10.1101/gad.1047403
  18. R. Weissleder, M.J. Pittet, Imaging in the era of molecular oncology. Nature 452(7187), 580–589 (2008). https://doi.org/10.1038/nature06917
  19. S. Shi, C. Xu, K. Yang, S. Goel, H.F. Valdovinos et al., Chelator-free radiolabeling of nanographene: breaking the stereotype of chelation. Angew. Chem. Int. Edit. 56(11), 2889–2892 (2017). https://doi.org/10.1002/anie.201610649
  20. S. Goel, C.G. England, F. Chen, W. Cai, Positron emission tomography and nanotechnology: a dynamic duo for cancer theranostics. Adv. Drug Deliv. Rev. 113, 157–176 (2017). https://doi.org/10.1016/j.addr.2016.08.001
  21. K. Hu, H. Wang, G. Tang, T. Huang, X. Tang, X. Liang, S. Yao, D. Nie, In vivo cancer dual-targeting and dual-modality imaging with functionalized quantum dots. J. Nucl. Med. 56(8), 1278–1284 (2015). https://doi.org/10.2967/jnumed.115.158873
  22. S. Shi, K. Yang, H. Hong, H.F. Valdovinos, T.R. Nayak et al., Tumor vasculature targeting and imaging in living mice with reduced graphene oxide. Biomaterials 34(12), 3002–3009 (2013). https://doi.org/10.1016/j.biomaterials.2013.01.047
  23. B.K. Seon, A. Haba, F. Matsuno, N. Takahashi, M. Tsujie et al., Endoglin-targeted cancer therapy. Curr. Drug Deliv. 8(1), 135–143 (2011). https://doi.org/10.2174/156720111793663570
  24. E. Fonsatti, H.J. Nicolay, M. Altomonte, A. Covre, M. Maio, Targeting cancer vasculature via endoglin/cd105: a novel antibody-based diagnostic and therapeutic strategy in solid tumours. Cardiovasc. Res. 86(1), 12–19 (2010). https://doi.org/10.1093/cvr/cvp332
  25. L.S. Rosen, M.S. Gordon, F. Robert, D.E. Matei, Endoglin for targeted cancer treatment. Curr. Oncol. Rep. 16(2), 365 (2014). https://doi.org/10.1007/s11912-013-0365-x
  26. M. Paauwe, P. ten Dijke, L.J. Hawinkels, Endoglin for tumor imaging and targeted cancer therapy. Expert Opin. Ther. Targets 17(4), 421–435 (2013). https://doi.org/10.1517/14728222.2013.758716
  27. F. Chen, W. Bu, Y. Chen, Y. Fan, Q. He et al., A sub-50-nm monosized superparamagnetic Fe3O4@SiO2 T2-weighted MRI contrast agent: highly reproducible synthesis of uniform single-loaded core-shell nanostructures. Chem. Asian J. 4(12), 1809–1816 (2009). https://doi.org/10.1002/asia.200900276
  28. K.M. Taylor, J.S. Kim, W.J. Rieter, H. An, W. Lin, Mesoporous silica nanospheres as highly efficient mri contrast agents. J. Am. Chem. Soc. 130(7), 2154–2155 (2008). https://doi.org/10.1021/ja710193c
  29. F. Chen, H. Hong, Y. Zhang, H.F. Valdovinos, S. Shi, G.S. Kwon, C.P. Theuer, T.E. Barnhart, W. Cai, In vivo tumor targeting and image-guided drug delivery with antibody-conjugated, radiolabeled mesoporous silica nanoparticles. ACS Nano 7(10), 9027–9039 (2013). https://doi.org/10.1021/nn403617j
  30. S.P. Hadipour Moghaddam, M. Yazdimamaghani, H. Ghandehari, Glutathione-sensitive hollow mesoporous silica nanoparticles for controlled drug delivery. J. Control. Release (2018). https://doi.org/10.1016/j.jconrel.2018.04.032. (Epub ahead of print)
  31. M. Kong, J. Tang, Q. Qiao, T. Wu, Y. Qi, S. Tan, X. Gao, Z. Zhang, Biodegradable hollow mesoporous silica nanoparticles for regulating tumor microenvironment and enhancing antitumor efficiency. Theranostics 7(13), 3276–3292 (2017). https://doi.org/10.7150/thno.19987
  32. M.S. Kang, R.K. Singh, T.H. Kim, J.H. Kim, K.D. Patel, H.W. Kim, Optical imaging and anticancer chemotherapy through carbon dot created hollow mesoporous silica nanoparticles. Acta Biomater. 55, 466–480 (2017). https://doi.org/10.1016/j.actbio.2017.03.054
Read More
Author biographies are not available.
Download this PDF file
PDF
Statistic
Read Counter : 3859 Download : 2933

Most read articles by the same author(s)